The human induced pluripotent stem cells (hiPSCs) available through the NIGMS Repository have been reprogrammed using various technologies, some of which are licensed by third party entities. Researchers purchasing hiPSCs from the NIGMS Repository are responsible for any limited use label licenses (LULLs) applicable to the cell line purchased. It is the researcher’s responsibility to investigate whether the intended use of the cell line requires him/her to obtain commercial rights to the technology. Below are links to LULLs which may apply to samples in the NIGMS Repository.
To obtain rights for the commercial use of Sendai reprogrammed cell lines please contact ID Pharma Co., Ltd. at info@idpharma.jp and Academia Japan, Inc. directly at license@ips-ac.co.jp or through ID Pharma Co., Ltd. If you have any questions regarding LULLs, please contact the entity holding the license directly.
The creation of your gene-edited cell line (the "Product") using CRISPR/Cas9 technology is provided by The Coriell Institute for Medical Research ("Coriell") under a license agreement with The Broad Institute, Inc. ("Broad") that contains certain limitations and obligations. By purchasing this Product, you, the Limited Licensee, hereby agree to be bound by the terms of the Limited License set forth below. Additional capitalized terms are defined below. Limited Licensee is granted the non-transferable right to use the Product created by or distributed by Coriell solely for research conducted by or on behalf of such Limited Licensee in accordance with all of the following requirements:
“Commercial Purposes” means (a) the practice, performance or provision of any method, process or service, or (b) the manufacture, sale, use, distribution, disposition or importing of any product, in each case (a) or (b) for consideration, e.g., a fee, or on any other commercial basis.
“Field” means use as a research tool for research purposes including, without limitation, the identification, screening, characterization and/or evaluation of compounds whether for toxicology, proficiency, performance or otherwise; provided, however, the Field shall expressly exclude (a) any clinical use, including, without limitation, diagnostic and prognostic use, (b) any human germline modification, including modifying the DNA of human embryos or human reproductive cells, (c) any in vivo veterinary or livestock use, or (d) the manufacture, distribution, importation, exportation, transportation, sale, offer for sale, marketing, promotion or other exploitation or use of, or as, a testing service, therapeutic or diagnostic for humans or animals.
“Indemnitees” means each Institution and the Howard Hughes Medical Institute, their affiliates, and their current and former trustees, directors, officers, faculty, affiliated investigators, students, employees, medical and professional staff and agents and their respective successors, heirs and assigns.
“Institution” means each of Broad, the Massachusetts Institute of Technology (“MIT”), the President and Fellows of Harvard College (“Harvard”), the University of Iowa Research Foundation “Iowa”), the University of Tokyo (“UTokyo”), The Rockefeller University (“Rockefeller”), New York University (“NYU”), New York Genome Center (“NYGC”), and Whitehead Institute of Biomedical Research (“WHI”) individually, and “Institutions” means Broad, MIT, Harvard, Iowa, UTokyo, Rockefeller, NYU, NYGC, and WHI, collectively.
“Licensed Process” means any process, method or service, performed, (a) the performance, sale or offer for sale of which process, method or service, or part thereof, would infringe (without the license granted under this Agreement) or is claimed by at least one claim of the Patent Rights.
“Patent Rights” are those rights claimed in one or more issued patents or patent applications related to CRISPR/Cas9 technology obtained by Broad and under license by Coriell, as well as (I) any substitutions, divisions, continuations, reissues, renewals, re-examinations or extensions thereof, (II) any continuations-in- 4 part thereof, to the extent the claims are directed to subject matter specifically described in such patent or patent application, and (III) any application claiming priority to a provisional application thereof, to the extent the claims are directed to subject matter specifically described in such provisional patent application; (c) any letters patents and/or the equivalent issuing therefrom in any jurisdiction based on, and only to the extent of, any of the foregoing; and (d) any foreign or international equivalents of any of the foregoing, including without limitation any applications filed under the Patent Cooperation Treaty.
“Related Material” means any progeny, modification or derivative of a Product.
If you have any questions regarding LULLs, please contact the entity holding the license directly.